{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:35:26Z","timestamp":1776814526344,"version":"3.51.2"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020865","name":"Takeda Pharma Vertrieb GmbH & Co.KG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is limited data on advanced therapy outcomes in second-line vs. first-line advanced treatment of patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD).<\/jats:p>\n                  <jats:p>We conducted a retrospective health claims study of patients with UC and CD in Germany. We analyzed claims data from 2014 to 2021, and compared therapy persistence and dose escalation in first- (1L) and second-line (2L) advanced therapy. Our analysis included the approved therapies adalimumab (ADA), infliximab (IFX), ustekinumab (UST) and vedolizumab (VDZ) for both UC and CD patients and golimumab (GOL) and tofacitinib (TOF) for UC patients.<\/jats:p>\n                  <jats:p>2,948 patients were included in the study and initiated 1L advanced therapy. Of these, 823 patients started a 2L advanced therapy. Time on treatment was generally shorter in 2L compared to 1L: In UC patients, persistence rates at 2 years ranged from 52.5% to 71.9% for 1L, and from 40.1% to 69.1% for 2L. In CD patients, persistence rates ranged from 66.6% to 86.6% for 1L, and from 59.9% to 74.3% for 2L. We observed more frequent dose escalations in 2L than in 1L for all advanced therapies except GOL in UC patients.<\/jats:p>\n                  <jats:p>Our study indicates that advanced therapies have shorter persistence and require higher doses when used as 2L treatment compared to 1L treatment. Future studies on reliable response predictors in patients with UC or CD receiving advanced treatments are likely to improve the selection of more efficacious 1L therapy.<\/jats:p>","DOI":"10.1055\/a-2836-5222","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:42:18Z","timestamp":1776811338000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn\u2019s Disease \u2013 A Retrospective Cohort Analysis of Healthcare Claims Data"],"prefix":"10.1055","author":[{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Agaplesion Markus Hospital, Germany","place":["Frankfurt am Main"],"department":["Medical Clinic I"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-4521","authenticated-orcid":false,"given":"Niels","family":"Teich","sequence":"additional","affiliation":[{"name":"Internal Medicine Group Practice for Digestive and Metabolic Diseases, Germany","place":["Leipzig"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Takeda Pharma Vertrieb GmbH & Co KG, BE, Germany","place":["Berlin"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"S\u00fcnwoldt","sequence":"additional","affiliation":[{"name":"Takeda Pharma Vertrieb GmbH & Co KG, BE, Germany","place":["Berlin"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5886-2785","authenticated-orcid":false,"given":"Evelyn","family":"Reinhard","sequence":"additional","affiliation":[{"name":"WIG2 GmbH, Germany","place":["Leipzig"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Borchert","sequence":"additional","affiliation":[{"name":"WIG2 GmbH, Germany","place":["Leipzig"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kudernatsch","sequence":"additional","affiliation":[{"name":"Takeda Pharma Vertrieb GmbH & Co KG, BE, Germany","place":["Berlin"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","article-title":"Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part II","volume":"24","author":"SR Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3748\/wjg.v22.i3.1017","article-title":"How to predict clinical relapse in inflammatory bowel disease patients","volume":"22","author":"E Liverani","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"B Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ncp.11146","article-title":"Dietary therapies for adult and pediatric inflammatory bowel disease","volume":"39","author":"J Deas","year":"2024","journal-title":"Nutr Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of Inflammatory Bowel Disease: A Comprehensive Review","volume":"8","author":"Z Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/1744666x.2023.2292768","article-title":"Management and treatment optimization of patients with mild to moderate ulcerative colitis","volume":"20","author":"F D\u02bcAmico","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052789","article-title":"Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease","volume":"25","author":"P Puca","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/ibd\/izab228","article-title":"Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD","volume":"28","author":"NM Noor","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking Through the Therapeutic Ceiling: What Will It Take?","volume":"162","author":"T Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis","volume":"100","author":"S St\u00e4nder","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12876-025-04022-7","article-title":"Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data","volume":"25","author":"A Dignass","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"MK Goel","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases \u2013 a Danish nationwide cohort study","volume":"55","author":"M Zhao","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231201728","article-title":"10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification \u2013 a nationwide population-based study","volume":"16","author":"HM Koo","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource","volume":"18","author":"C Kapizioni","year":"2024","journal-title":"Journal of Crohn\u02bcs and Colitis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12876-024-03378-6","article-title":"Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY","volume":"24","author":"N Krugliak Cleveland","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/ibd\/izad245","article-title":"Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY","volume":"30","author":"N Krugliak Cleveland","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jcag\/gwae040","article-title":"Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis","volume":"8","author":"L Targownik","year":"2025","journal-title":"J Can Assoc Gastroenterol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2836-5222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:42:20Z","timestamp":1776811340000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2836-5222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1055\/a-2836-5222","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}